FBXO11 Targets BCL6 for Degradation and Is Inactivated in Diffuse Large B-Cell Lymphomas

Nature - United Kingdom
doi 10.1038/nature10688
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment

Biomedical Sciences
2017English

Lenalidomide in Diffuse Large B-Cell Lymphomas

Advances in Hematology
Hematology
2012English

Microenvironment Expression in Diffuse Large B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Diffuse Large B-Cell Lymphomas Are Metabolically Heterogeneous

Cancer Discovery
Oncology
2012English

BAFF-R Is Expressed on B-Cell Lymphomas Depending on Their Origin, and Is Related to Proliferation Index of Nodal Diffuse Large B-Cell Lymphomas

Journal of clinical and experimental hematopathology : JCEH
Medicine
2010English

P27KIP1 Is Abnormally Expressed in Diffuse Large B-Cell Lymphomas and Is Associated With an Adverse Clinical Outcome

British Journal of Cancer
Cancer ResearchOncology
1999English

Negative Autoregulation of BCL-6 Is Bypassed by Genetic Alterations in Diffuse Large B Cell Lymphomas

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2002English

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Oncologist
Cancer ResearchMedicineOncology
2018English

A Study of the Newer Prognostic Markers in Diffuse Large B Cell Lymphomas

Medical Journal Armed Forces India
Medicine
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy